Bioatla (BCAB) investor relations material

Company overview and business model

• Clinical-stage biopharma developing conditionally active biologics (CABs) for solid tumors; antibodies are designed to bind in acidic tumor environments while limiting binding in healthy tissue.

• CAB platform spans antibody-drug conjugates, T-cell-engaging bispecifics and other antibody modalities; lead programs include BA3011, BA3021, BA3071 and BA3182.

• Strategic process launched March 2, 2026 to evaluate asset sales, licensing, partnerships or other transactions; further BA3182 enrollment paused and BA3021 Phase 3 timing under review.

• As of February 1, 2026, intellectual property portfolio included 868 patents and applications: 597 issued, 13 allowed and 258 pending.

Financial performance and metrics

• H1 2026 revenue was $6.5M from the Context license amendment; net loss was $5.9M versus $34.0M H1 2025. Q2 2026 net income was $0.5M versus an $18.7M loss.

• FY2025 net loss was $59.6M versus $69.8M FY2024; collaboration revenue was $2.0M versus $11.0M, with no product-sales revenue to date.

• Cash and cash equivalents were $1.5M at June 30, 2026, versus $7.1M at December 31, 2025; H1 2026 operating cash use was $5.7M.

• Accumulated deficit reached $551.5M at June 30, 2026; current cash was insufficient for 12 months of operations, and the filing cited substantial doubt about going concern.

Use of proceeds and capital allocation

• Resales by Yorkville are for its account; proceeds from those resales go to Yorkville, not to the issuer.

• Potential SEPA proceeds of up to $40M gross are intended primarily for working capital, general corporate purposes and R&D, alongside existing cash; management retains broad allocation discretion.

• No minimum use of the SEPA is required; the actual amount raised depends on elected advances, market price, trading volume, ownership and registration limits.